๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Cannock, Leeds, London, Sheffield
2023-11-08
Active, closed
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
NCT05904717REM Sleep Behavior Disorder
Syntara
Phase 2
40
Oxford
2023-11-08
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Pfizer
Phase 3
1,571
Isleworth, Southampton, London
2023-11-08
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
Bristol-Myers Squibb
Phase 2
227
Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees
2023-11-07
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Cardiff, Dundee, Glasgow, London, York
2023-11-07
Active, closed
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907Ulcerative Colitis
AbbVie
Phase 3
122
Sheffield, London, Southampton, Birmingham
2023-11-06
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
London
2023-11-06
Active, closed
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
NCT06046820Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Inozyme Pharma
Phase 3
27
Manchester
2023-11-05
By invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
NCT06066580Becker Muscular Dystrophy
Edgewise Therapeutics, Inc.
Phase 2
260
Salford, London, Newcastle
2023-11-02
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Leicester, Liverpool, London, Middlesbrough, Nottingham
2023-11-01
Recruiting
Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)
NCT05762211Transplant Complication
MaaT Pharma
Phase 2
387
Cardiff
2023-10-31
Active, closed
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Metastatic Uveal Melanoma
IDEAYA Biosciences
Phase 2/3
420
Glasgow, Metropolitan Borough of Wirral, Northwood
2023-10-31
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
LeonaBio
Phase 3
600
Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees
2023-10-31
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
United Therapeutics
Phase 3
698
Birmingham, Cambridge, Edinburgh, London, Manchester, Perth
2023-10-30
Recruiting
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
NCT05658497Multiple Sclerosis
Biogen
Observational
908
Salford
2023-10-27
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon
2023-10-27
Recruiting
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758Solid Tumours
Orion Corporation, Orion Pharma
Phase 1/2
315
Leicester, London, Sheffield
2023-10-26
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
1,600
Leeds, London, Manchester
2023-10-26
Recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
Nuvectis Pharma, Inc.
Phase 1
140
Edinburgh, London
2023-10-26
By invitation
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
NCT06126380Kidney Transplant Rejection
Eledon Pharmaceuticals
Phase 2
132
Oxford
2023-10-25
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
1,057
Birmingham, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough, Exeter
2023-10-25
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 3
1,020
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
895
Birmingham, Blackpool, Bury St Edmunds, Colchester, London, Truro
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenstrรถm Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
BeOne Medicines
Phase 2
114
Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth
2023-10-23
Recruiting
ZNN Bactiguard Retrograde Femoral Nails PMCF Study
NCT05276674Femoral Fracture
Zimmer Biomet
Observational
100
Leeds, Manchester, Stockport
2023-10-23
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
Hoffmann-La Roche
Phase 3
182
Glasgow, Lincoln, London, Manchester, Oxford, Plymouth
2023-10-22
Active, closed
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333Congestive Heart Failure
AskBio Inc
Phase 2
150
Manchester, Leeds, Cardiff, Glasgow, London
2023-10-20
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.
Phase 2
260
Liverpool, Belfast, Birmingham, Cambridge, London
2023-10-18
Recruiting
The GORE VBX FORWARD Clinical Study: A Comparison of the GOREยฎ VIABAHNยฎ VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
NCT05811364Aortoiliac Occlusive Disease, Peripheral Arterial Disease
W.L.Gore & Associates
Not applicable
244
Canterbury, London, Southampton
2023-10-17
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
Celgene
Phase 3
79
Birmingham, London
2023-10-16
Recruiting
DAREONโ„ข-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim
Phase 2
204
Leicester, London, Manchester, Newcastle upon Tyne
2023-10-13
Active, closed
A Study to Evaluate the Effectiveness and Safety of Dysportยฎ for the Prevention of Chronic Migraine in Adults
NCT06047444Chronic Migraine
Ipsen
Phase 3
759
Brighton, Brixton
2023-10-12
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
311
Harrow, Salford, Southampton
2023-10-12
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
684
Harrow, London, Reading, Salford
2023-10-12
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
AbbVie
Phase 3
1,500
High Wycombe, Brighton, Gloucester, London, Oxford, Harrow, Salford
2023-10-11
Active, closed
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
NCT06109649Vitiligo
Clinuvel, Inc.
Phase 3
200
London, Manchester
2023-10-11
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
Merck Sharp & Dohme LLC
Phase 3
14,550
Bristol, Exeter, Walsall, London, Newcastle upon Tyne, Clydebank, Romford, Corby
2023-10-09
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Aberdeen, Burton-on-Trent, Cambridge, Derby, Guildford, Ipswich, Lancaster, Leeds
2023-10-05
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 3
306
London, Birmingham, Chapel Allerton
2023-10-03
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
Novartis Pharmaceuticals
Phase 3
106
Belfast, Cardiff, London, Manchester, Salford
2023-10-02
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
AbbVie
Phase 3
90
London
2023-10-02
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
NCT06008080Aortic Stenosis
Abbott Medical Devices
Observational
1,000
London, Middlesbrough, Stoke-on-Trent, Wolverhampton
2023-09-29
By invitation
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
NCT05967351Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
400
London, Oxford, Newcastle upon Tyne
2023-09-27
Active, closed
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
NCT06007677Hereditary Angioedema
Astria Therapeutics, Inc.
Phase 2
56
Cambridge, Leeds
2023-09-26
Active, closed
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
NCT05786573Warm Autoimmune Hemolytic Anemia
Zenas BioPharma (USA), LLC
Phase 3
134
Plymouth, Canterbury
2023-09-25
Active, closed
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
160
London, Manchester, Oxford
2023-09-25
Active, closed
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
London
2023-09-22
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
PharmaMar
Phase 3
469
Birmingham, Cambridge, Liverpool, London, Manchester, Oxford
2023-09-21
Active, closed
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06052306Metastatic Castration-resistant Prostate Cancer
Bayer
Phase 1
232
Cambridge, London, Sutton, Newcastle upon Tyne
2023-09-20
By invitation
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
NCT06075537Mucopolysaccharidosis II
Denali Therapeutics Inc.
Phase 2/3
99
Birmingham, London, Manchester
2023-09-20
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals
Phase 3
410
Cambridge, Edinburgh, Birmingham, London, Manchester
2023-09-18
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3
1,130
Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle
2023-09-18
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Akouos, Inc.
Phase 1/2
22
London
2023-09-15
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
1,255
Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough
2023-09-14
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
687
Edinburgh, London
2023-09-14
Recruiting
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
NCT06259019Coronary Artery Disease
PlaqueTec Ltd
Not applicable
300
Bournemouth, Bristol, Cambridge, Norwich
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
GlaxoSmithKline
Phase 2/3
300
Wakefield, Birmingham, Leeds, London, Portsmouth
2023-09-13
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
argenx
Phase 3
240
Liverpool, London, Salford
2023-09-12
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Birmingham, Bradford, Bristol, Cambridge, Canterbury, Cardiff, Carshalton, Coventry
2023-09-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjรถgren's Syndrome
NCT05946941Sjรถgren's Syndrome
Bristol-Myers Squibb
Phase 3
774
Southampton, Wolverhampton, Birmingham, Cannock
2023-09-11
Recruiting
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938Community-acquired Pneumonia
Biotest
Phase 3
590
Plymouth, London, Glasgow, Guildford, Cardiff
2023-09-09
Active, closed
Clairleafแต€แดน: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230Bronchiectasis
Boehringer Ingelheim
Phase 2
268
Dundee, Scotland
2023-09-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
230
Belfast, Blackpool, Colchester, Essex, Northwood, Nottingham, Oxford
2023-09-08
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG
Phase 2
80
Birmingham, Cambridge, Liverpool, London, Manchester, Preston
2023-09-07
Recruiting
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
NCT06092034Danon Disease
Rocket Pharmaceuticals Inc.
Phase 2
14
London
2023-09-05
Active, closed
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
NCT06033833Asthma
Sanofi
Phase 2
335
Bradford
2023-09-05
Active, closed
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
NCT05835492Chronic Obstructive Pulmonary Disease
my mhealth Ltd
Observational
200
Liskeard, Bristol
2023-09-04
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Leicester, London
2023-09-01
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269Rheumatoid Arthritis
AnaptysBio, Inc.
Phase 2
420
London, Manchester
2023-08-31
By invitation
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
NCT05883748Erythropoietic Protoporphyria
Disc Medicine, Inc
Phase 2/3
230
London, Dundee, Salford
2023-08-31
Active, closed
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Cytokinetics
Phase 3
500
Dundee, Glasgow, Liverpool, London, Oxford
2023-08-31
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Ascentage Pharma Group Inc.
Phase 3
350
Birmingham, Glasgow, London
2023-08-31
Recruiting
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
AviadoBio Ltd
Phase 1/2
18
Cambridge, Cardiff, London
2023-08-30
Active, closed
Pediatric Patients Aged 1 to 6 Years With APDS
NCT05693129APDS
Pharming Technologies B.V.
Phase 3
16
London
2023-08-30
By invitation
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
NCT05962398Hemophilia B
CSL Behring
Observational
56
London, Cambridge, Southampton
2023-08-30
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Ilford, Swinton, London, Aberdeen, Chertsey, Edinburgh, Leeds, Motherwell
2023-08-28
Active, closed
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482Huntington Disease
Novartis Pharmaceuticals
Phase 2
144
Birmingham, Cardiff, London, Manchester
2023-08-25
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Recruiting
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
NCT05878860X-linked Retinoschisis
Atsena Therapeutics Inc.
Phase 3
97
Oxford
2023-08-22
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
London
2023-08-21
Active, closed
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304Advanced or Metastatic Solid Tumors
Erasca, Inc.
Phase 1
86
City of London, Glasgow
2023-08-17
Active, closed
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 2
41
Glasgow, London
2023-08-16
Active, closed
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
NCT05987527Kidney Transplant Rejection, End Stage Renal Disease
Sangamo Therapeutics
Observational
11
Oxford
2023-08-15
Active, closed
Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema
NCT05949645Emphysema or COPD
Apreo Health, Inc.
Not applicable
30
London
2023-08-15
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941Prostate Cancer
Novartis Pharmaceuticals
Phase 4
700
Sutton, Barnet, Cambridge, Glasgow, Middlesbrough
2023-08-14
By invitation
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
NCT05844449Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
174
Cardiff, London
2023-08-11
Recruiting
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
NCT05997615Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 1
437
London
2023-08-10
Recruiting
Confirmatory Clinical Evaluation of Novilaseยฎ Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954Malignant Neoplasm of Breast
Novian Health Inc.
Not applicable
122
London, Oxford
2023-08-09
Active, closed
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
NCT05899673Alpha1-Antitrypsin Deficiency
Takeda
Phase 3
31
Cambridge, Edinburgh
2023-08-08
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic
Merck Sharp & Dohme LLC
Phase 3
735
Nottingham, London-Camden
2023-08-08
Recruiting
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312Paroxysmal Nocturnal Hemoglobinuria (PNH)
ADARx Pharmaceuticals, Inc.
Phase 1/2
50
London
2023-08-07
Active, closed
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
NCT05818553SCN2A Encephalopathy, SCN8A Encephalopathy
Praxis Precision Medicines
Phase 2/3
77
Glasgow, London
2023-08-02
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
GlaxoSmithKline
Phase 3
892
Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.
Phase 2
220
Barnet, London, Manchester, Nottingham
2023-07-31
Active, closed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593Geographic Atrophy
Belite Bio, Inc
Phase 3
429
Great Yarmouth, Harrow, London
2023-07-27
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Bretton, London, Southampton, Northampton, Londonderry, Luton, Portsmouth
2023-07-25
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Incyte Corporation
Phase 1
570
Cambridge, London, Manchester, Newcastle upon Tyne
2023-07-24
Rows per page Showing 1501–1600 of 2847
Previous 14 15 16 17 18 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=16

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.